unknown
Stage
2002
Founded
4
Investors
About
Am-Pharma develops ilofotase alfa, a recombinant human alkaline phosphatase enzyme replacement therapy targeting hypophosphatasia (HPP), a rare genetic metabolic disorder, to improve bone mineralization and address related symptoms in adult patients.
Explore Am-Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.